Changzhu Wu1, Ning Zhai, Chao Guan, Wenyu Ji. 1. Department of Otorhinolaryngology, the First Affiliated Hospital of China Medical University, Beijing, China. wuchangzhu@sina.com
Abstract
OBJECTIVE: To study whether Integrin linked kinase (ILK) is involved in the development and progression of laryngeal squamous cell carcinomas (LSCC). METHOD: We examined the expression of ILK in 64 LSCC (LSCC group) and 10 normal laryngeal mucosa (control group) using reverse transcription polymerase chain reaction (RT-PCR) and analyzed the relationship with clinic pathological parameters. RESULT: The expression of ILK mRNA was significantly higher in 64 LSCC tissue (0. 644 +/- 0. 098) than in normal laryngeal mucosa tissues (0.032 +/- 0.026, P <0.05). The expression of ILK mRNA in LSCC with the metastasis of lymph nodes (0. 867 +/- 0.247) was significantly higher than those without metastasis (0.389 +/- 0.199, P <0.05). With the development of clinical T-stages of LSCC, the expression of ILK mRNA in LSCC increases. There was no significant difference between different clinical stage groups (P > 0.05). CONCLUSION: These results suggest that ILK may participate not only in LSCC but also in invasion and metastasis of LSCC. ILK might be a novel molecular marker for prognosticating metastases and prognosis of LSCC.
OBJECTIVE: To study whether Integrin linked kinase (ILK) is involved in the development and progression of laryngeal squamous cell carcinomas (LSCC). METHOD: We examined the expression of ILK in 64 LSCC (LSCC group) and 10 normal laryngeal mucosa (control group) using reverse transcription polymerase chain reaction (RT-PCR) and analyzed the relationship with clinic pathological parameters. RESULT: The expression of ILK mRNA was significantly higher in 64 LSCC tissue (0. 644 +/- 0. 098) than in normal laryngeal mucosa tissues (0.032 +/- 0.026, P <0.05). The expression of ILK mRNA in LSCC with the metastasis of lymph nodes (0. 867 +/- 0.247) was significantly higher than those without metastasis (0.389 +/- 0.199, P <0.05). With the development of clinical T-stages of LSCC, the expression of ILK mRNA in LSCC increases. There was no significant difference between different clinical stage groups (P > 0.05). CONCLUSION: These results suggest that ILK may participate not only in LSCC but also in invasion and metastasis of LSCC. ILK might be a novel molecular marker for prognosticating metastases and prognosis of LSCC.